Skip to content

Douwe De Boer

Instituto Nacional do Desporto, Laboratório de Análises de Dopagem e Bioquímica, Av. Prof. Egas Moniz (Estádio Universitário), 1600-190 Lisbon, Portugal. douwedeboer@mail.telepac.pt

3 papers in the library · 206 citations · publishing 2004-2005

Papers

A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs.

Pharmacy world & science : PWS April 1, 2004 Douwe De Boer, Ingrid Bosman 89 citations

Between 1994 and 2002, products sold in Dutch smartshops as synthetic drugs were purchased and analyzed. Most tablets contained one of the phenethylamine designer drugs 2C-B, 2C-T-2, or 2C-T-7, with new drugs appearing on the market roughly every three years. Accompanying leaflets provided extensive but partly misleading information. Scientific data on health risks and detection of these 2C-series drugs was scarce. No intoxications had been reported in the European Union, and no centralized legal actions had been taken. The absence of observed intoxications may justify the lack of EU legal actions, but could also reflect toxicologists' inability to detect these substances or unawareness of the phenomenon. EU authorities should promote availability of standards, validated assays, and scientific knowledge.

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.

Toxicology January 5, 2005 Helena Carmo, Jan G Hengstler, Douwe De Boer et al. 85 citations

The psychoactive designer drug 2C-B is broken down by liver cells from humans, monkeys, dogs, rabbits, rats, and mice through oxidative deamination and demethylation, producing several metabolites. A previously unknown metabolite, 4-bromo-2,5-dimethoxy-phenol (BDMP), appeared only in mouse cells, while another metabolite, 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), formed in human, monkey, and rabbit cells but not in dog, rat, or mouse cells. Toxic effects on liver cells varied little across species but showed large differences among cells from three human donors, indicating that individual human variation may be more important than species differences in determining 2C-B toxicity.

Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences November 25, 2004 Helena Carmo, Douwe De Boer, Fernando Remião et al. 32 citations

The psychoactive drug 2C-B, sold as 'Ecstasy', is metabolized in mice, producing several metabolites detectable in urine by GC/MS. Unchanged 2C-B and these metabolites were identified, providing data that may help understand the drug's biological and toxicological effects and aid forensic analysis of samples from human abusers.